Galaxy StocksBiogen Idec Inc. (NASDAQ:BIIB) Jumps over 34% in 3 Months As Positive MS …Galaxy StocksShares of Biogen Idec Inc. (NASDAQ:BIIB) got a raise in the opening minutes of trading on Thursday following the firm declared results from its multip…
RPT-BRIEF-Emergent Biosolutions to expand clinical trial of TRU-016 and …ReutersApril 5 (Reuters) – April 5 (Reuters) – Emergent Biosolutions Inc : * To expand front line CLL clinical trial of TRU-016 and rituximab based on strong patient enrollment …
Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and …Fort Mills TimesEmergent BioSolutions Inc. (NYSE: EBS) today announced its decision to expand the protocol for its ongoing Phase 1b, single arm, open label study (Protocol …
|
Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and …
MarketWatch (press release) “Emergent is pleased with the progress of our Phase 1b study of TRU-016 in combination with rituximab in front line patients with CLL. The strong enrollment and the encouraging early data from this open label study are expected to facilitate an … |
 Hannover Zeitung |
Daclizumab HYP halbiert die Wahrscheinlichkeit von MS-Schüben
MyHandicap Auf der Suche nach neuen Medikamenten gegen die schubförmige Multiple Sklerose (MS) haben Forscher unter Studienleitung der Neurologie des RUB-Klinikums St. Josef Hospital (Prof. Dr. Ralf Gold) einen erfolgversprechenden Kandidaten getestet: … Multicenterstudie: Neues Medikament könnte bei Multiple Sklerose die …DMSG Multiple Sklerose Nachrichten Erfolg versprechend: Neues Medikament gegen Multiple Sklerose – idwInformationsdienst Wissenschaft (Pressemitteilung) Multiple Sklerose: Bochumer Wissenschaftler erforschen neue …Westfalen heute |
|
Hospitals to get tough on smoking relatives, potential cure for insomnia and …
Pulse Drugs no longer listed include rituximab for blood cancers, alemtuzumab for leukaemia, erlotinib for lung cancer, trabectedin for ovarian cancer and plerixafor for myeloma. With such perplexing news, it’s heartening to hear the Daily Mail has … |
 Telegraph.co.uk |
Cancer patients facing race against clock for drugs in fund ‘betrayal’
Telegraph.co.uk Drugs which are not on the central list include rituximab for blood cancers, one of the most commonly requested treatments under the previous fund, as well as alemtuzumab for leukaemia, erlotinib for lung cancer, trabectedin for ovarian cancer, and … The great cancer betrayal: Number of treatments on approved list for patients …Daily Mail |
 Science Codex |
Hepatitis A Steals Skin From Infected Cells to Hide From Immune System
Geekosystem Researchers and clinicians have long thought that the hepatitis A vaccine — which is one of the most effective vaccines ever developed — worked by recruiting antibodies to destroy cells infected by the disease. Since the virus is cloaked, though … Hepatitis A Virus Discovered to Cloak Itself in Membranes Hijacked from …Science Daily (press release) |
Rituximab improved dexamethasone response rates in immune thrombocytopeniaHealioResearchers randomly assigned 71 patients to dexamethasone 40 mg/day for 4 days, and 62 patients were assigned this dexamethasone regimen plus rituximab (Rituxan, Genentech…
Latinos PostBreakthrough Reported in Creating Antibodies to Fight HIV/AIDSLatinos PostFrom the onset of infection, the human immune system generates antibodies designed to attach to — and destroy — HIV. And for the first few weeks, the study resear…